Breast Cancer

The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.

Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.

Datopotamab deruxtecan previously showed statistically significant improvement in progression-free survival in patients with HR+, HER2-low, or HER2-negative breast cancer.

Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.

Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.

Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.

ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.

DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.

In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.

A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Early data appear to highlight encouraging efficacy and tolerability outcomes with Bria-IMT in patients with metastatic breast cancer.

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.